Incyte Licenses Cache of Therapeutic Antibodies to Genentech | GenomeWeb

NEW YORK, Oct. 23 - Incyte Genomics and Genentech have struck a licensing deal that covers patents covering therapeutic antibodies to four proteins discovered by Incyte, the companies said on Tuesday.

Under terms of the agreement, Incyte is entitled to receive clinical development milestone payments for the antibodies and royalties if any are commercialized.

Financial terms of the agreement and the intended clinical uses of the four antibodies were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."